Not an SEC registrant

Voronoi Inc.

Customers

1 disclosed

Suppliers

None disclosed

Largest customer

—

No % disclosed

Named-customer revenue

—

No estimate available

Latest period

Dec 31, 2025

10-K filed 2026-02-23

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Customers 1

Companies Voronoi Inc. discloses as major customers, as a share of Voronoi Inc. revenue. 1 active, 0 lapsed.

Company	% of Voronoi Inc. revenue	Est. revenue	Period	Trend	Status	Source
ORIC Oric Pharmaceuticals, Inc.	Named	—	FY 2025-12-31	—	Active	10-K 2026-02-23
In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi Inc. development and commercialization rights to a brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 mutations.As of December 31, 2025, the Company had an accumulated deficit of $692.2 million. 10-K filed 2026-02-23 Period FY 2025-01-01 to 2025-12-31Accession 0001193125-26-064005

Alerts are coming

Get an email when Voronoi Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.